Long-Term Effect of Group Support Psychotherapy on Depression and HIV Treatment Outcomes: Secondary Analysis of a Cluster Randomized Trial in Uganda.

Journal: Psychosomatic medicine

Volume: 84

Issue: 8

Year of Publication: 2022

Affiliated Institutions:  From the Department of Psychiatry, College of Health Sciences (Nakimuli-Mpungu, Seggane), Makerere University, Kampala, Uganda; Departments of Medicine (Smith) and Psychiatry and Behavioral Sciences (Smith), Duke University Medical Center, Durham, North Carolina; Department of Psychology (Wamala), Center for Victims of Torture; Department of Mental Health, Faculty of Medicine (Okello), Gulu University, Gulu; The AIDS Support Organization (TASO) (Birungi, Etukoit), Kampala, Uganda; Department of Mental Health, Bloomberg's School of Public Health (Mojtabai), Johns Hopkins University, Baltimore, Maryland; Department of Epidemiology, Pittsburgh Graduate School of Public Health (Nachega), University of Pittsburgh, Pittsburgh, Pennsylvania; Stellenbosch Center for Infectious Disease, Department of Medicine (Nachega), Stellenbosch University, Stellenbosch, South Africa; Department of International Health, Bloomberg's School of Public Health (Nachega), Johns Hopkins University, Baltimore, Maryland; MTEK Sciences Inc (Harari), Vancouver, British Columbia; and Department of Clinical Epidemiology and Biostatistics (Mills), McMaster University, Hamilton, Ontario, Canada.

Abstract summary 

We aimed to determine the effect of group support psychotherapy (GSP) compared with group HIV education (GHE) on depression and HIV treatment outcomes 24 months after treatment. We further aimed to investigate the mediating role of depression and antiretroviral therapy (ART) adherence in the relationship between GSP and viral load suppression.Thirty HIV clinics across three districts were randomly assigned to deliver either GSP or GHE for depression. Depression and optimal (≥95%) ART adherence was assessed at baseline and 6, 12, 18, and 24 months after treatment. Viral load was drawn from the medical charts at baseline and 12 and 24 months after treatment. Multilevel mixed-effects regression models and generalized structural equation modeling were used to estimate 24-month outcomes and mediation effects.Participants ( N = 1140) were enrolled from HIV clinics offering either GSP ( n = 578 [51%]) or GHE ( n = 562 [49%]). Fewer GSP than GHE participants met the criteria for depression at 24 months after treatment (1% versus 25%; adjusted odds ratio [aOR] = 0.002, 95% confidence interval [CI] = 0.0002-0.018). More GSP than GHE participants reported optimal (≥95%) ART adherence (96% versus 88%; aOR = 20.88, 95% CI = 5.78-75.33) and improved viral suppression (96% versus 88%; aOR = 3.38, 95% CI = 1.02-11.02). The indirect effects of GSP through sequential reduction in depression and improvement in ART adherence at 12 months may partially explain the higher viral suppression rates at 24 months in GSP than GHE groups.In settings where the HIV epidemic persists, depression treatment with GSP may be critical for optimal HIV treatment outcomes.Trial Registration: The Pan African Clinical Trials Registry, number PACTR201608001738234.

Authors & Co-authors:  Nakimuli-Mpungu Etheldreda E Smith Colin M CM Wamala Kizito K Okello James J Birungi Josephine J Etukoit Micheal M Mojtabai Ramin R Nachega Jean B JB Harari Ofir O Musisi Seggane S Mills Edward J EJ

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Chibanda D, Benjamin L, Weiss HA, Abas M. Mental, neurological, and substance use disorders in people living with HIV/AIDS in low-and middle-income countries. J Acquir Immune Defic Syndr 2014;67:S54–67.
Authors :  11
Identifiers
Doi : 10.1097/PSY.0000000000001128
SSN : 1534-7796
Study Population
Male,Female
Mesh Terms
Anti-HIV Agents
Other Terms
Study Design
Randomized Control Trial,Cross Sectional Study
Study Approach
Country of Study
Uganda
Publication Country
United States